News

If you wish to view this page in your preferred RSS reader, you can access the RSS feed here.

 

We are thrilled to have more than 5000 patients registered on Add-Aspirin which reflects the hard work and dedication of staff across the UK and India. Over 2300 participants have now been registered in the breast cohort, and more than 3900 participants have been randomised overall. The 5000th participant was registered to the breast cohort from Ipswich Hospital. ...

The Add-Aspirin Translational Research Manual has recently been updated to v3.0. The manual can be downloaded from the members area of the Add-Aspirin website. Please store a copy in your Investigator Site File and mark V2.0 as ‘superseded’.

Main changes include:

  • Updated contact details (including biobank addresses)
  • Guidance on batch-submission of tumour blocks
  • Addition of the urinary thromboxane sub-study: instructions for urine collection. This only applies to centres who have already been invited to take part.

To centres taking part in the urinary thromboxane sub-study, please await further instructions. You should not start collecting urine until we have been in touch regarding the sub-study launch, which we anticipate to be within the next month.

Please pass this onto the relevant people in your team and don’t hesitate to get in touch if you have any queries.

The Add-Aspirin Delegation Log template has now been updated to include a list of delegated study tasks.

This does not need to be completed retrospectively, but version 3.0 should be used going forward for any new staff joining the trial, or any staff whose study tasks have changed since first completion on the log (for example, a Research Nurse who is now dispensing drug).

Please log in to the members area to download the new template ready for your site file.

New research has suggested that individuals who suffer from both heart failure and type II diabetes may benefit from taking daily aspirin. The study reviewed medical records from more than 12,000 individuals living with these conditions in the UK over a number of years. This was not a clinical trial - a trial is the best way to demonstrate a definite link between aspirin use an ...

Cancer Research UK launched an international study today, to answer the final questions before aspirin could be recommended to reduce cancer risk. Studies have estimated that widespread use of low-dose aspirin could lead to a 10% drop in the number of people dying from some cancers, but for every 17 lives saved by preventing cancer or heart attacks there would be two deaths ca ...